Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-13
2007-02-13
Berch, Mark (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S230000, C544S281000, C544S117000, C548S371700, C548S357500, C548S953000, C546S223000
Reexamination Certificate
active
10762959
ABSTRACT:
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
REFERENCES:
patent: 3155670 (1964-11-01), Janssen
patent: 3161644 (1964-12-01), Janssen
patent: 4925846 (1990-05-01), Deacon et al.
patent: 4944790 (1990-07-01), Moser et al.
patent: 4992442 (1991-02-01), Tsujitani et al.
patent: 5086057 (1992-02-01), Takiguchi et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5571813 (1996-11-01), Buhter et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5744491 (1998-04-01), Boigegrain et al.
patent: 5744493 (1998-04-01), Boigegrain et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5843951 (1998-12-01), Inoue et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6060478 (2000-05-01), Gilligan et al.
patent: 6100259 (2000-08-01), Xiang et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6355631 (2002-03-01), Bouchard et al.
patent: 6372743 (2002-04-01), Darrow et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6476038 (2002-11-01), Darrow et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2001/0053788 (2001-12-01), Lange et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0019421 (2002-02-01), Biberman et al.
patent: 2002/0035102 (2002-03-01), Achard et al.
patent: 2002/0091114 (2002-07-01), Plot-Grosjean et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2002/0128302 (2002-09-01), Maruani et al.
patent: 2002/0188007 (2002-12-01), Barth et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2003/0125330 (2003-07-01), Gilligan
patent: 2003/0139386 (2003-07-01), Cote et al.
patent: 2003/0199536 (2003-10-01), Thomas et al.
patent: 2004/0072833 (2004-04-01), Nakai et al.
patent: 2004/0077650 (2004-04-01), Dow
patent: 2004/0092520 (2004-05-01), Griffith
patent: 2004/0122074 (2004-06-01), Dow
patent: 2004/0157839 (2004-08-01), Griffith
patent: 2005/0203106 (2005-09-01), Gudmundsson et al.
patent: 293220 (1994-08-01), None
patent: 1354884 (2003-10-01), None
patent: JP 05125079 (1993-05-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 01/15609 (2000-05-01), None
patent: WO 01/24798 (2001-04-01), None
patent: WO 01/028557 (2001-04-01), None
patent: WO 01/029007 (2001-04-01), None
patent: WO 01/032629 (2001-05-01), None
patent: WO 01/032663 (2001-05-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 01/85092 (2001-11-01), None
patent: WO 02053565 (2002-07-01), None
patent: WO 02/076949 (2002-10-01), None
patent: WO 03/006007 (2003-01-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/018060 (2003-03-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/020314 (2003-03-01), None
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 03/027069 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/075660 (2003-09-01), None
patent: WO 03/077847 (2003-09-01), None
patent: WO 03/078413 (2003-09-01), None
patent: WO 03/082190 (2003-10-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 03/082256 (2003-10-01), None
patent: WO 03/082833 (2003-10-01), None
patent: WO 03/084943 (2003-10-01), None
patent: WO 03/086288 (2003-10-01), None
patent: WO 03/087037 (2003-10-01), None
patent: WO 03095455 (2003-11-01), None
patent: WO 04/012617 (2004-02-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Huestis, M.A. et al, Arch Gen Psychiatry. Apr. 2001;58(4):322-8.
Pertwee, R.G., Forsch Komplementarmed. Oct. 1999; 6 Suppl. 3:12-5.
Giuffrida, A. et al, J Pharmacol Exp Ther. Jul. 2001;298(1):7-14.
Barth F, Rinaldi-Carmona M., Curr Med Chem. Aug. 1999;6(8):745-55. Abstract only PMID: 10469889.
Brotchie JM., Curr Opin Pharmacol. Feb. 2003;3(1):54-61, Abstract only PMID:12550742.
Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L.J Pharmacol Exp Ther. Jul. 2003;306(1):363-70.
Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG, Br J Pharmacol. Feb. 2003;138(4): 53.
Anonymous, “Developments in the Treatment of Parkinson's Disease”, Drug Therap. Bull., 37, 1999, 36-40.
Burke, J.R. et al, Postgraduate Medicine, 1999, pp. 85, 86, 89, 90, 93, 94, & 96.
Shoulson, I., Science, 282, 1998, 1072-1074.
Poncelet, M.; Psychopharmacology; 1999; 144; 144-150.
Mas-Nieto, M.; British Journal of Pharmacology; 2001; 132; 1809-1816.
Chaperon, F.; Psychopharmacology; 1998; 135; 324-332.
Sanudo-Pena; M.C.; Neuroscience Letters; 1997; 223; 125-128.
Mansbach, R.S.; Psychopharmacology; 1996; 124; 315-322.
Mechoulam, R.; TRENDS in Pharmacological Science; 2003; 24(6); 266-268.
Cohen, C.; Behavioural Pharmacology; 2002; 13; 451-463.
Wolff, M.C.; European Jouranl of Pharmacology; 2003; 477; 213-217.
Di Marzo, V.; FASEB Journal; 2000; 14; 1432-1438.
Ferrer, B.; European Journal of Neuroscience; 2003; 18; 1607-1614.
Croci, T.; British Journal of Pharmacology; 2003; 140; 115-122.
Senga, K., et al., “Synthesis and Antischistosomal Activity of Certain Pyrazolo[1,5-a]pyrimidines,”J Med Chem,24, 610-613 (1981).
Sugimoto, O., et al., “A facile halgenation of some hydroxyheterocycles using triphenylphosphine and N-halosuccinimide,”Tetra Lett, 40, 7477-7478 (1990).
Almansa, C., et al., “Synthesis and SAR of a New Series of COX-2 Selective Inhibitors: Pyrazolo[1,5-a]pyrimidines,”J. Med. Chem, 44, 350-361, (2001).
Tzavara, E.T., et al., “The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions,”J Pharmacol, 138, 544-553 (2003).
Racz, I., et al., “A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking,”J Neurosci,23(6), 2453-2458 (2003).
Croci, T., et al., “Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents,”Brit J Pharmacol,140, 115-122 (2003).
DaSilva, G.E., et al., “Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats,”Neurosci Let,349, 49-52 (2003).
Wang, L., et al., “Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice,”PNAS, 100(3), 1393-1398 (2003).
Ruiu, S., et al., “Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor,”J Pharmacol Exp Therap, 306, 363-370 (2003).
Howlett, A.C., et al., “International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors,”Pharmacol Rev,54, 161-202 (2002).
Gomez, R., et al., “A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding,”J. Neurosci,22(21), 9612-9617 (2002).
Wiley, J.L., et al., “Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation,”J Pharmacol Exp Therap,296(3), 1013-1022 (2001).
Lellemand, F., et al., “Effe
Benson Gregg C.
Berch Mark
Moore Susanna
Musser Arlene K.
Pfizer Inc.
LandOfFree
Cannabinoid receptor ligands and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cannabinoid receptor ligands and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor ligands and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3890436